tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michael Ulz, 204 are a BUY (66.67%), 98 are a HOLD (32.03%), 4 are a SELL (1.31%).
Analyst Michael Ulz, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 46.87% that have a potential upside of 41.48% achieved within 171 days. Previously, Michael Ulz worked at BAIRD.
Michael Ulz’s has documented 596 price targets and ratings displayed on 57 stocks. The coverage is on Healthcare, Financial Services, Industrials sectors.
Most recent stock forecast was given on IONS, Ionis Pharmaceuticals.
Analyst best performing recommendations are on NRIX (NURIX THERAPEUTICS).
The best stock recommendation documented was for AKRO (AKERO THERAPEUTICS) at 12/19/2022. The price target of $40 was fulfilled within 1 day with a profit of $1.22 (3.15%) receiving and performance score of 31.46.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 28-Jul-2017
$205
$22.5 (12.33%)
5 years 6 months 5 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold Since 03-May-2021
$173
$-9.5 (-5.21%)
$156
5 years 6 months 7 days ago
(03-May-2021)
18/29 (62.07%)
$2.73 (1.60%)
667
Hold Since 04-Feb-2021
$190
$7.5 (4.11%)
$190
5 years 6 months 16 days ago
(26-Apr-2021)
11/14 (78.57%)
$23 (13.77%)
420
Buy Since 06-Sep-2019
$175
$-7.5 (-4.11%)
$165
5 years 9 months 6 days ago
(04-Feb-2021)
3/3 (100%)
$19.41 (12.48%)
397
Buy Since 08-Feb-2018
$166
$-16.5 (-9.04%)
$179
5 years 9 months 6 days ago
(04-Feb-2021)
21/21 (100%)
$10.41 (6.69%)
711
Which stock is Michael Ulz most bullish on?
Which stock is Michael Ulz most reserved on?
What Year was the first public recommendation made by Michael Ulz?
